Hematopoietic Stem Cells Derived from Hemogenic Endothelial Cells by Episomal Plasmid Gene Transfer

EPO published international patent application EP3621630A1 as a grant of exclusive rights for methods of producing hematopoietic stem and progenitor cells from hemogenic endothelial cells using episomal plasmid vectors. The patent covers compositions and methods where episomal plasmid gene transfer enables stable expression in blood cell precursors without integration. The application was filed under the Patent Cooperation Treaty and designates 35 European states including Germany, France, UK, Italy, Spain, and the Netherlands.

Biotechnology companies and research institutions developing gene-modified cell therapies, particularly those focused on hematopoietic stem cell engineering or blood disorders, should assess whether their products or methods fall within the scope of these claims. Competitors seeking to commercialize similar technologies in European markets may need to pursue licensing arrangements or design-around strategies to avoid infringement of this granted patent.